NDAORALCAPSULEPriority Review
Approved
May 2021
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRUSELTIQ (infigratinib phosphate) is an oral small-molecule fibroblast growth factor receptor (FGFR) inhibitor approved by the FDA in May 2021. It is indicated for cholangiocarcinoma patients with FGFR2 gene fusions or rearrangements. The drug works by selectively inhibiting FGFR signaling in tumor cells that harbor these genetic alterations.
$0.351MPart D
Peak8.3 years to LOEEarly-stage rare disease indication with limited Part D claims suggests modest commercial team and significant growth opportunity as diagnosis rates improve and reimbursement expands.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TRUSELTIQ is a rare-indication precision oncology product with modest current sales but significant unmet-need potential in cholangiocarcinoma; roles on this team focus on building diagnosis awareness, establishing reimbursement frameworks, and executing niche-market strategies. Career value lies in early-stage rare disease commercialization expertise and potential for brand growth as genomic testing expands.
Brand Manager
Worked on TRUSELTIQ at Helsinn? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.